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Background: The utility of fish oil supplements (FOS) in coronary disease remains controversial. The characteristics of those who do and do not 
use FOS post-acute myocardial infarction (AMI) are unknown as are the associations of use with subsequent mortality.
design: The 24-site TRIUMPH study collected extensive information on 4340 AMI patients at admission and 1, 6, and 12 months post discharge. 
After excluding those using FOS at admission (n=651), who died in hospital (n=19), and lost to follow up (n=650), we analyzed 74 characteristics 
associated with starting FOS within 1 year of discharge. We found 25 differences between FOS users and non-users (p<0.001) and used 19 in 
hierarchical Cox regression models (including propensity matching) to assess the association of FOS use with 2-year mortality.
results: Within 1 year of AMI, 773 (26%) patients reported using FOS. FOS users were healthier in many ways (Table). Using propensity methods 
and adjusting for all of these factors, the adjusted HR for 2-year mortality was 0.52 (95% CI=0.417, 0.661; p<0.001).
conclusion: In routine clinical practice, post-MI patients who initiate FOS are healthier and financially more secure than those who do not. Despite 
and after adjusting for these differences, initiation of FOS was associated with a 48% reduction in 2-year mortality. Although a beneficial effect of 
FOS itself cannot be ruled out, the likelihood of unmeasured confounding in these findings is substantial.
Variables Most Different Between Groups (from 19 included in the model; all p<0.001)
Started FOS (n = 773) Did not Start FOS (n = 2247)
White/Caucasian, n (%) 609 (78.8%) 1424 (63.7%)
Short of money at end of month, n (%) 109 (14.4%) 520 (23.6%)
Don’t work for pay, n (%) 309 (40.4%) 1214 (54.5%)
Participated in Cardiac Rehab, n (%) 285 (44.6%) 388 (22.6%)
Has Insurance, n (%) 647 (85.7%) 1687 (76.6%)
History of Chronic Kidney Disease, n (%) 28 (3.6%) 171 (7.6%)
History of Chronic Heart Failure, n (%) 35 (4.5%) 195 (8.7%)
History of Stroke, n (%) 17 (2.2%) 129 (5.7%)
History of Prior MI, n (%) 105 (13.6%) 486 (21.6%)
